Sparsentan Reduces Proteinuria and Slows Kidney Decline in Pediatric FSGS
HOUSTON — Sparsentan therapy showed a sustained reduction in proteinuria and a lower risk of progression to kidney failure compared to irbesartan in children with focal segmental glomerulosclerosis (FSGS), according to recent study data.
Study Findings
Pediatric patients treated with sparsentan (Filspari, Travere Therapeutics), a dual endothelin-angiotensin II receptor antagonist, were more likely to achieve complete or partial remission of proteinuria. Michelle N. Rheault, MD, director of pediatric nephrology at the University of Minnesota, presented the two-year results for children enrolled in the DUPLEX study at ASN Kidney Week.
“Based on the recent PARASOL study, reduction of proteinuria is a strong predictor of slowed progression of chronic kidney disease, so this is a very promising therapy for children who otherwise do not have other options for treatment.”
“Importantly, the safety profile of sparsentan was similar to irbesartan, a drug we use every day to treat children with kidney disease.”
Trial Details
- The phase 3 DUPLEX trial enrolled 371 patients aged 8 to 75 years with FSGS.
- Sparsentan targets both endothelin and angiotensin II receptors to reduce proteinuria.
- Therapy in children led to significant clinical benefits over irbesartan.
Author's Summary
Sparsentan offers a promising and well-tolerated treatment option that significantly reduces proteinuria and slows kidney disease progression in children with FSGS.